Home/MAIA Biotechnology/Vlad Vitoc, MD, MBA

VV

Vlad Vitoc, MD, MBA

Chief Executive Officer and Chairman

MAIA Biotechnology

Therapeutic Areas

MAIA Biotechnology Pipeline

Drug	Indication	Phase
Ateganosine (THIO)	Non-Small Cell Lung Cancer (NSCLC)	Phase 2
Second-generation telomere targeting agents	Cancer	Pre-clinical/Research

Leadership Team at MAIA Biotechnology

Sergei M. Gryaznov, PhD

Chief Scientific Officer

Jeffrey C. Himmelreich

Head of Finance

View full MAIA Biotechnology profile